Form 4: Viatris Inc. Director Dillon JoEllen Lyons Reports Stock Transactions
SEC Form 4
Director Dillon JoEllen Lyons reported the acquisition and disposal of Viatris Inc. common stock and restricted stock units, including sales under a pre-arranged trading plan.
Summary
- On March 3, 2024, Director Dillon JoEllen Lyons acquired 17,970 shares of Viatris Inc. common stock through the vesting of restricted stock units (RSUs) and 885 shares related to dividend equivalent units (DEUs).
- Also on March 3, 2024, Lyons disposed of 17,970 RSUs and 884.8005 DEUs.
- On March 5, 2024, Lyons sold 20,000 shares of common stock at a price of $12.36 per share.
- These sales were executed under a pre-arranged trading plan adopted on November 28, 2023, intended to comply with Rule 10b5-1(c) of the Securities Exchange Act of 1934.
- Following these transactions, Lyons directly owns 58,714 shares of Viatris Inc. common stock and indirectly owns 18 shares through a spouse.
- Lyons also holds 18,204 unvested restricted stock units that will vest on March 4, 2025.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing primarily reports routine stock transactions by a director under a pre-arranged trading plan. There is no indication of positive or negative sentiment towards the company's prospects.
Future Outlook
The reporting person holds 18,204 unvested RSUs that will vest on March 4, 2025.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. These filings are monitored by investors to gain insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Comparing the insider trading activity of Viatris Inc. to similar pharmaceutical companies like Teva Pharmaceutical Industries or Mylan (prior to its merger with Upjohn to form Viatris) would require analyzing their respective Form 4 filings over a comparable period.
- Analyzing the volume and frequency of insider transactions, as well as the nature of the transactions (e.g., sales vs. purchases), can provide insights into the sentiment of company insiders regarding the stock's future performance.
- However, it's important to note that insider trading activity can be influenced by various factors, including personal financial planning and diversification strategies, and may not always be indicative of the company's overall prospects.
Key Dates
| Date | Description |
|---|---|
| November 28, 2023 | Date the reporting person adopted a written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). |
| March 3, 2023 | Date of the RSUs previously granted that accrued dividend equivalent units. |
| March 3, 2024 | Date of RSU vesting and acquisition of common stock. |
| March 5, 2024 | Date of common stock sale. |
| March 4, 2025 | Vesting date for remaining Restricted Stock Units. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.